Editorial media
Science news

A promising fatty liver treatment may raise cancer risk

July 11, 2026Carlos Mendoza1 ΠΌΠΈΠ½

A recent, surprising study sheds new light on a potential pitfall in the quest for effective fatty liver treatments. Researchers have discovered that blocking the enzyme Caspase-2, which some strategies aim to inhibit for therapeutic benefit, might ironically elevate the risk of chronic liver damage and even cancer in the long run. The findings suggest that without the presence of this enzyme, liver cells tend to grow abnormally large and accumulate significant genetic damage. This cellular disruption can lead to inflammation, progressive scarring, and ultimately, the formation of tumors, especially as individuals age. While short-term inhibition of Caspase-2 could offer some benefits, such as reducing the immediate effects of fatty liver disease, the long-term implications, according to this new research, appear to be hazardous to liver health.